Drugs / GSK3439171A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03627494 | Aug 2018 → Aug 2019 | muscular dystrophy | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3439171A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03627494 ↗ |
| Route | Oral | “Single and Repeat Oral Doses of GSK3439171A” NCT03627494 ↗ |